- Home
- SLNH vs RNXT Comparison
SLNH vs RNXT Comparison
Compare SLNH & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLNH
- RNXT
- Stock Information
- Founded
- SLNH 1961
- RNXT 2012
- Country
- SLNH United States
- RNXT United States
- Employees
- SLNH N/A
- RNXT N/A
- Industry
- SLNH EDP Services
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- SLNH Technology
- RNXT Health Care
- Exchange
- SLNH Nasdaq
- RNXT Nasdaq
- Market Cap
- SLNH 29.4M
- RNXT 31.6M
- IPO Year
- SLNH N/A
- RNXT 2021
- Fundamental
- Price
- SLNH $1.45
- RNXT $1.03
- Analyst Decision
- SLNH
- RNXT Strong Buy
- Analyst Count
- SLNH 0
- RNXT 1
- Target Price
- SLNH N/A
- RNXT $9.00
- AVG Volume (30 Days)
- SLNH 511.7K
- RNXT 218.8K
- Earning Date
- SLNH 03-31-2025
- RNXT 03-31-2025
- Dividend Yield
- SLNH N/A
- RNXT N/A
- EPS Growth
- SLNH N/A
- RNXT N/A
- EPS
- SLNH N/A
- RNXT N/A
- Revenue
- SLNH $39,867,000.00
- RNXT N/A
- Revenue This Year
- SLNH N/A
- RNXT N/A
- Revenue Next Year
- SLNH N/A
- RNXT N/A
- P/E Ratio
- SLNH N/A
- RNXT N/A
- Revenue Growth
- SLNH 163.48
- RNXT N/A
- 52 Week Low
- SLNH $1.36
- RNXT $0.77
- 52 Week High
- SLNH $8.80
- RNXT $1.86
- Technical
- Relative Strength Index (RSI)
- SLNH 33.67
- RNXT 35.37
- Support Level
- SLNH $1.36
- RNXT $1.00
- Resistance Level
- SLNH $1.75
- RNXT $1.18
- Average True Range (ATR)
- SLNH 0.16
- RNXT 0.10
- MACD
- SLNH -0.01
- RNXT -0.03
- Stochastic Oscillator
- SLNH 17.65
- RNXT 6.00
About SLNH Soluna Holdings Inc.
Soluna Holdings Inc is a U.S.-based company that conducts operations through its subsidiary. The group is engaged in the mining of cryptocurrency through data centers that can be powered by renewable energy sources. The data centers buy every excess megawatt to use for batch-oriented, computing-intensive processes such as cryptocurrency mining or machine learning which is a low-risk and low-friction solution to use as a smartphone.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.